エピソード

  • Ep 70 - How Abbott and Cordis are working to change the interventional vascular business
    2021/08/13
    Let's get interventional. This week, we talk with leaders from Abbott and Cordis about their plans to advance of medtech's stablest business. Duke Rohlen, executive chair, will explain to co-host Tom Salemi why he led the purchase of Cordis from Cardinal. Meanwhile, Dr. Nick West, CMO and DVP of vascular at Abbott, updates Associated Editor Sean Whooley on the Xience pipeline. This week's Newmarker's Newsmakers brings the big news from Abbott, Heartflow, Intersect ENT, Intuitive, Medtronic, Philips, and Resmed. Subscribe to this podcast on all major podcast applications!
    続きを読む 一部表示
    1 時間 4 分
  • Ep 69 - Why Koya CEO Doraiswamy is tackling lymphedema; Follow Todd Brinton’s unlikely path to Edwards
    2021/08/06
    This week’s episode focuses on the entrepreneurs. We open up with an interview with Andy Doraiswamy, founder and CEO of Koya Medical, a company he founded to help find a therapy for his ailing father. Then we revisit with Dr. Todd Brinton, chief scientific officer and corporate vice president at Edwards. This interview initially ran in May 2020 but we’re playing it again to amplify the unusual path that entrepreneurs take to find success.
    続きを読む 一部表示
    1 時間 4 分
  • Ep 68 - What's next in Diabetes? CeQur moving toward manufacturing, Medtronic readying for the long haul
    2021/07/30
    This week's episode focuses on new hope for people with diabetes. Brad Paddock, CEO of CeQur, explains how its "wearable pen" can deliver insulin in a better way while Sean Salmon, head of Medtronic's diabetes business, reviews that company's growing portfolio. He also gives insights on its intriguing partnership with the private equity group, Blackstone. Chris Newmarker, executive editor of life sciences, drops a weighty Newmarker's Newmakers featuring stories from Hillrom, Baxter, NeuroMetrix, Philips, Medtronic and BD. Subscribe to this podcast on all major podcast apps.
    続きを読む 一部表示
    1 時間 20 分
  • Ep 67 - Hear why Merck KGaA and INBRAIN Neurolectronics see such great promise in Bioelectronic medicine
    2021/07/23
    The bioelectronics industry is poised to take off so we visited with Carolina Aguilar, CEO/Co-founder, INBRAIN Neuroelectronics about the field's potential. Chris Newmarker, executive editor of life sciences at MassDevice, delivers his Newmarker's Newsmakers highlighting news from Dexcom, NeuroMetrix, Nevro, Ancora and the Galien foundation. Subscribe to this podcast on Google, Amazon, Apple, Spotify and other major podcast channels.
    続きを読む 一部表示
    42 分
  • Ep 66 - Hear from the CEOs of two surgical robotics companies that together just raised over $1 billion
    2021/07/16
    Vicarious Surgical and CMR Surgical recently combined to raise over $1 billion from public and private investors. Big money clearly as found surgical robotics. Now what? We connect with Per Vegard Nerseth, the new CEO of CMR. Nerseth comes to CMR from the robotics industry, so he brings deep industry understanding of what it will take to get CMR to the next level. The company closed on $600 million for a Series D, which is likely the largest private medtech investment in history. Later, we reconnect with Adam Sachs, co-founder and CEO of Vicarious Surgical. Sachs walks us through the process of merging with a SPAC (not for the faint-hearted.) With over $400 million in hand, Vicarious is bringing in senior talent and moving to a legacy filled new HQ to prepare for its next stage. Chris Newmarker, executive editor of life sciences at MassDevice, brings his Newmarker's Newsmakers highlighting news from Stryker, Heartflow, Hillrom, BardyDx, TransMedics and Imperative Care. Subscribe to this podcast on every major podcast channel!
    続きを読む 一部表示
    52 分
  • Ep 65 - Leerink sees surge in home dialysis; Vensana, LRV detail deal in CardioDx start-up Cleerly Health
    2021/07/09
    This week we’ll focus on investor insights. First, we’ll talk with Danielle Antalffy, managing director at SVB Leerink. Antalffy covers most of the major medtechs but we’ll focus on a new report she issues on sugaring home-based dialysis business. What does this mean for Outset specifically? More broadly, do other medtechs need to build out their at-home/connectivity function? Also, what does NeuroPace’s success mean for other medtech companies. In a follow up to our interview with Dr. James Min, CEO of Cleerly Health, we talk with two venture investors in the early heart attack risk detection company. Justin Klein, MD, of Vensana Capital walks us through the steps he took before leading the company’s recent $43 million Series B round. Tripp Peake of LRV Health explains why the company interests his venture firm’s limited partner base. This is an opportunity for entrepreneurs to better understand the venture capital due diligence process. Chris Newmarker, executive editor of life sciences, delivers his Newmarker’s Newsmakers brings top news from Conformis, Stryker, Siemens Healthineers, Abbott, Medtronic and Levita Magnetics. LIKE! FOLLOW! SUBSCRIBE! We’re on most major podcast channels.
    続きを読む 一部表示
    1 時間 17 分
  • Ep 64 - Why Minnetronix made its own medical device. How Cleerly raised $43m to upend Cardiovascular Dx
    2021/06/25
    In this week's DeviceTalks Weekly Podcast, Minnetronix CEO Jeremy Maniak explains how the CMO is using internal know how to develop medical devices that can be sold by outside partners. We also hear from Dr. James Min of Cleerly Health about that company's start and the process that went into raising $43 million. Chris Newmarker, executive editor of life sciences at MassDevice, is back to deliver his NewmarkersNewsmakers including news from Costa Rica, Vicarious Surgical, Ethicon, Medtronic and ResMed. Subscribe to this podcast today on all major podcast channels.
    続きを読む 一部表示
    1 時間 3 分
  • Ep 63 - How Arboretum Venture' Walker learned early in her medtech career to not take "No" as an answer
    2021/06/18
    Nicole J. Walker, managing partner, Arboretum Ventures, tells a unique medtech story that begins with her sick grandfather and follows up with her refusal to remove her foot from the door at Advanced Cardiovascular Systems. She says she learned early on that she may not always have all the answers when making a decision but she would have the instincts and mettle to push through. This combination moved through jobs at Guidant, Abbott, Baird and now Arboretum Ventures where she sees an enormous opportunity finding medical device companies.
    続きを読む 一部表示
    53 分